KR20200119243A - 비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙 - Google Patents

비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙 Download PDF

Info

Publication number
KR20200119243A
KR20200119243A KR1020207022313A KR20207022313A KR20200119243A KR 20200119243 A KR20200119243 A KR 20200119243A KR 1020207022313 A KR1020207022313 A KR 1020207022313A KR 20207022313 A KR20207022313 A KR 20207022313A KR 20200119243 A KR20200119243 A KR 20200119243A
Authority
KR
South Korea
Prior art keywords
osimertinib
platinum
treatment
egfr
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207022313A
Other languages
English (en)
Korean (ko)
Inventor
앤써니 프랜시스 패트릭 내시
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Priority to KR1020257043592A priority Critical patent/KR20260009945A/ko
Publication of KR20200119243A publication Critical patent/KR20200119243A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207022313A 2018-02-12 2019-02-11 비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙 Ceased KR20200119243A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257043592A KR20260009945A (ko) 2018-02-12 2019-02-11 비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862629166P 2018-02-12 2018-02-12
US62/629,166 2018-02-12
PCT/EP2019/053311 WO2019155059A1 (en) 2018-02-12 2019-02-11 Osimertinib for use in the treatment of non-small cell lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257043592A Division KR20260009945A (ko) 2018-02-12 2019-02-11 비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙

Publications (1)

Publication Number Publication Date
KR20200119243A true KR20200119243A (ko) 2020-10-19

Family

ID=65443828

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207022313A Ceased KR20200119243A (ko) 2018-02-12 2019-02-11 비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙
KR1020257043592A Pending KR20260009945A (ko) 2018-02-12 2019-02-11 비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257043592A Pending KR20260009945A (ko) 2018-02-12 2019-02-11 비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙

Country Status (15)

Country Link
US (4) US20200368231A1 (https=)
EP (2) EP4431154A3 (https=)
JP (2) JP2021513517A (https=)
KR (2) KR20200119243A (https=)
CN (2) CN116870008A (https=)
AU (2) AU2019219304A1 (https=)
BR (1) BR112020015507A2 (https=)
CA (1) CA3090010A1 (https=)
EA (1) EA202091841A1 (https=)
IL (1) IL276406A (https=)
MA (1) MA51823A (https=)
MX (1) MX2020008395A (https=)
SG (1) SG11202007414XA (https=)
TW (2) TWI868714B (https=)
WO (1) WO2019155059A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240126585A (ko) 2023-02-14 2024-08-21 박주현 좁은 전시공간에서 전시품의 360도 실감 영상투사식 전시장치

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3133766A1 (en) 2019-03-29 2020-10-08 Astrazeneca Ab Osimertinib for use in the treatment of non-small cell lung cancer
CN110433296A (zh) * 2019-08-16 2019-11-12 哈尔滨医科大学 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用
WO2021148396A1 (en) * 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2022120197A1 (en) * 2020-12-03 2022-06-09 Emory University Combinations of epidermal growth factor receptor inhibitors and sterol regulatory element-binding protein inhibitors for uses in cancer therapies
WO2022166794A1 (zh) * 2021-02-02 2022-08-11 贝达药业股份有限公司 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
US20240226101A1 (en) * 2021-04-30 2024-07-11 Suzhou Puhe BioPharma Co., Ltd. Pyrimidinylaminobenzenes for lung cancer treatment
CN114917231A (zh) * 2022-05-27 2022-08-19 杭州师范大学 β-榄香稀和奥希替尼药物组合在制备抗肺癌药物上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
EP3191523B1 (en) * 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
WO2016164217A1 (en) * 2015-04-09 2016-10-13 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
WO2017164887A1 (en) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods for treatment
US10813933B2 (en) * 2016-05-17 2020-10-27 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
US20200038398A1 (en) * 2017-03-10 2020-02-06 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240126585A (ko) 2023-02-14 2024-08-21 박주현 좁은 전시공간에서 전시품의 360도 실감 영상투사식 전시장치

Also Published As

Publication number Publication date
JP2023116537A (ja) 2023-08-22
AU2022203007B2 (en) 2024-07-04
EA202091841A1 (ru) 2020-10-28
TW202412804A (zh) 2024-04-01
US20240156815A1 (en) 2024-05-16
WO2019155059A1 (en) 2019-08-15
SG11202007414XA (en) 2020-09-29
US20230226059A1 (en) 2023-07-20
AU2022203007A1 (en) 2022-05-26
CN111683663A (zh) 2020-09-18
EP3752153A1 (en) 2020-12-23
MA51823A (fr) 2021-05-19
KR20260009945A (ko) 2026-01-20
EP4431154A3 (en) 2024-12-11
US20220184076A1 (en) 2022-06-16
CA3090010A1 (en) 2019-08-15
MX2020008395A (es) 2020-09-21
BR112020015507A2 (pt) 2021-01-26
TWI868714B (zh) 2025-01-01
US20200368231A1 (en) 2020-11-26
JP2021513517A (ja) 2021-05-27
IL276406A (en) 2020-09-30
EP4431154A2 (en) 2024-09-18
TW201941773A (zh) 2019-11-01
CN116870008A (zh) 2023-10-13
AU2019219304A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
AU2022203007B2 (en) Osimertinib for use in the treatment of non-small cell lung cancer
JP6695003B2 (ja) 癌のための併用療法
CN109310754A (zh) 使用包含抗erbb3抗体的联合疗法治疗er+、her2-、hrg+乳腺癌的方法
Fleckenstein et al. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial
Camidge et al. Management strategies for early-onset pulmonary events associated with brigatinib
US20250262225A1 (en) Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
HK40116781A (en) Osimertinib for use in the treatment of non-small cell lung cancer
Jänne et al. P1. 01-41 A Phase 2 Study of DS-8201a in HER2-Overexpressing or-Mutated Advanced Non-Small-Cell Lung Cancer
EP3389660B1 (en) Combination therapy for cancer
Urbanska et al. EP12. 01-07 Brigatinib restores disease control at second progression on osimertinib in metastatic EGFR ex19del mutated NSCLC with acquired EML4-ALK fusion
US20250195917A1 (en) Sequential transarterial chemoembolization, stereotactic body radiotherapy, and immunotherapy (start-fit) for hepatocellular carcinoma
Yang et al. HS-10296–a novel third generation EGFR tyrosine kinase inhibitor: results of the first-in-human phase 1 trial in patients with previously treated EGFR mutant advanced non-small-cell lung cancer
Luo et al. Ibrutinib Inhibits Tumor Progression, Alleviates Pain, and Protects the Tibia in a Bone Metastasis Model of Lung Cancer
Ziółek et al. Cancer of an unknown primary with PDZRN3-RAF1 fusion and ATR splice site mutation, with atypical chemosensitivity pattern
CN120035437A (zh) 用于治疗EGFR突变癌症的N-(1-((R)-1-丙烯酰基氮杂环庚烷-3-基)-7-氯-6-(((R)-四氢呋喃-3-基)氧基)-1H-苯并[d]咪唑-2-基)-2-甲基异烟酰胺(NX-019)
Brugière et al. What can we learn from a negative randomised controlled trial in bronchiolitis obliterans syndrome after lung transplantation?
Bekaii-Saab Case Study Series
CN116829152A (zh) 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
Crvenkova PUB023 Concomitant Chemoradiotherapy Treatment for Inoperable Brain Metastases in Non-Small Cell Lung Cancer Patients: Clinical Experience
Tariq et al. Cerebral aspergillosis presenting as a space occupying lesion of the brain
Jenkins et al. P-160 Acute radiation oesophagitis following treatment of NSCLC with Continuous Hyperfractionated Accelerated Radiotherapy (CHART)
Coucke A phase I trial on LBH 589 (panobinostat), a histone deacetylase inhibitor (HDAC i) in combination with external radiotherapy for the treatment of prostate cancer, esophageal cancer and head and neck cancer.
Coucke A phase I trial of sunitinib, a tyrosine kinase inhibitor (TKI) combined with ionizing irradiation in rectal cancer
Math et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-2 controlled trial 3
Coucke A dosimetric study comparing breast radiotherapy planned in the prone versus supine positions and via conformal 3D versus IMRT techniques

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104